Pere Ginès

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (25)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (5)

Harry de Koning

Erasmus University Rotterdam

NETHERLANDS

View details

Florence Wong

Professor

University of Toronto

CANADA

View details

Esteban Mezey

Professor Emeritus

Johns Hopkins University School of Medicine

UNITED STATES

View details

Marina Serper

Assistant Professor of Medicine

University of Pennsylvania

UNITED STATES

View details

Antoni Castells

University of Barcelona

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Pere Ginès

Research Interests

Explore related searches

Contact this professor

Articles (25)

Is it better to base care of patients on evidence even limited, or on opinions and good intentions?

Reply to: “Comment on <Moving diagnosis of liver fibrosis into the community>”

Development of Acute Kidney Injury in a Patient With Alcohol-Related Cirrhosis: The Importance of Diagnosing the Cause of Acute Kidney Injury

Moving diagnosis of liver fibrosis into the community

Revisiting the use of albumin in patients with cirrhosis – trial design matters

Liver Health: An Emerging Concept

Variation in intention-to-treat survival by MELD subtypes: all models created for end-stage liver disease are not equal

Screening for liver fibrosis: lessons from colorectal and lung cancer screening

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Steatotic Liver Disease in Patients With Type 2 Diabetes Mellitus: Growing Evidence But Not Yet There

Population screening for cirrhosis

Shortening the albumin challenge from 48 to 24 hours may lead to overdiagnosis of hepatorenal syndrome-acute kidney injury and overtreatment with terlipressin

Hepatorenal Syndrome in Cirrhosis

Privacy-Preserving Federated Survival Support Vector Machines for Cross-Institutional Time-To-Event Analysis: Algorithm Development and Validation

Organ dysfunction and failure in liver disease

Screening for fibrosis to diagnose liver diseases early: the LIVERSCREEN project

Noninvasive assessment of hepatic decompensation

Medications for alcohol use disorder promote abstinence in alcohol-associated cirrhosis: Results from a systematic review and meta-analysis

EASL International Recognition Award Recipient 2022: Prof. Patrick S. Kamath

Reply to: “Acute-on-chronic liver failure in East-Asia: an underestimated issue with limited data”

Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis

Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases

Editorial: microRNAs for the diagnosis of fatty liver disease in the population—are we inching closer towards the target?

Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases

Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population‐based study

Are We Ready to Evaluate Adrenal Function in Patients With Decompensated Cirrhosis and Acute-on-Chronic Liver Failure?

Collaborators (5)

Harry de Koning

Florence Wong

Esteban Mezey

Marina Serper

Antoni Castells

Make your next move.